TD Cowen initiated coverage of Maze Therapeutics (MAZE) with a Buy rating and no price target The company’s MZE829, and oral APOL1 inhibitor, ...
Is the AI arms race slowing down? Microsoft Corp., a leading contender in the artificial intelligence arena, has reportedly ...
The latest TD Cowen report shows that Microsoft has been canceling data center leases, hinting the tech giant faces an ...
Fresh from questioning whether AI will provide all the economic benefits it is expected to deliver over the next five years, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback